Liver Transplant
📧 Sign up to get email alerts when something new happens for Liver Transplant.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant [NA]
A Johns Hopkins University-led clinical study evaluating technology-enabled strategies to improve medication adherence in youths who have un…
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Incentive Spirometer in Liver Transplant Recipients [NA]
A completed clinical trial evaluated the use of an incentive spirometer in liver transplant recipients. The sponsor of the study is Cairo Un…
-
FDA approval · 2025-07-15FDA Approved: SIROLIMUS — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved Rising Pharma Holdings, Inc.'s original application for sirolimus, a generic immunosuppressant used to prevent organ transp…
-
CLINICAL_TRIALS trial_result · 2024-11-01Clinical Trial Update: A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time [Phase 2]
This Phase 2 pediatric trial compares tacrolimus formulations Advagraf and Prograf in heart, kidney, and liver transplant recipients to asse…
-
FDA approval · 2024-09-26FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (Aurobindo Pharma Limited)
The FDA approved the original application for mycophenolate mofetil from Aurobindo Pharma Limited, granting generic approval for use in tran…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-09-20FDA Approved: TACROLIMUS — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for tacrolimus by Mylan Pharmaceuticals Inc., enabling changes to its labeling. This relates to …
-
FDA approval · 2024-05-29FDA Approved: MYCOPHENOLIC ACID — Original Application (Novugen Pharma (USA) LLC.)
FDA approved an original application for mycophenolic acid, enabling a generic version of the immunosuppressant used to prevent organ transp…
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: Liver Transplantation With Tregs at UCSF [Phase 1, Phase 2]
A multi-phase clinical trial on liver transplantation involving regulatory T cells (Tregs) at UCSF was terminated, with results posted in 20…
-
FDA approval · 2024-04-08FDA Approved: ENVARSUS XR — Supplemental Application (Veloxis Pharmaceuticals, Inc)
FDA approved a supplemental application for ENVARSUS XR (tacrolimus extended-release) submitted by Veloxis Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: High Versus Low Blood-Pressure Target in the Post Operative Care of Liver Transplantation A Randomized, Controled, Open and Unicentric Trial. [Phase 3]
A Phase 3 randomized trial comparing high versus low blood pressure targets in the postoperative care of liver transplantation was completed…
-
CLINICAL_TRIALS withdrawal · 2023-12-19Clinical Trial Update: Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients [Phase 2, Phase 3]
A clinical trial studying perioperative Remodulin in liver transplant recipients was withdrawn at the Phase 2/3 stage.
-
FDA approval · 2023-09-18FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Accord Healthcare Inc.)
The FDA approved a supplemental application for Accord Healthcare's generic mycophenolate mofetil, supporting its use to prevent organ trans…
-
FDA approval · 2023-09-14FDA Approved: ENVARSUS XR — Supplemental Application (Veloxis Pharmaceuticals, Inc)
FDA approved a supplemental application for ENVARSUS XR (tacrolimus) from Veloxis Pharmaceuticals, Inc., typically affecting the product's l…
-
CLINICAL_TRIALS trial_result · 2022-07-05Clinical Trial Update: Intravenous Ketamine Infusion on Postoperative Analgesia of Living Liver Donors [Phase 4]
A Phase 4 clinical trial update evaluating the effect of intravenous ketamine infusion on postoperative analgesia in living liver donor surg…
-
CLINICAL_TRIALS trial_result · 2021-12-10Clinical Trial Update: Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine [Phase 2]
Phase 2 clinical trial evaluating phenotypic precision medicine to optimize immunosuppression dosing in liver and kidney transplant recipien…
-
CLINICAL_TRIALS trial_result · 2021-09-21Clinical Trial Update: A Cohort Study of Operationally Tolerant Allograft Recipients
A cohort study on operational tolerance in kidney and liver transplant recipients has terminated; results posted in 2021.
-
FDA approval · 2021-08-11FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil hydrochloride) submitted by Genentech, authorizing an update to …
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for Mycophenolate mofetil submitted by Strides Pharma Science Limited. The approval covers the gener…
-
CLINICAL_TRIALS trial_result · 2021-04-30Clinical Trial Update: Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients [Phase 4]
Phase 4 trial update on CertiroBell tablet plus tacrolimus in primary living donor liver transplant recipients evaluating efficacy and safet…
-
FDA approval · 2021-04-21FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves Hikma Pharmaceuticals USA Inc.'s supplemental application for Mycophenolate mofetil, a generic immunosuppressant used to preven…
-
FDA approval · 2021-03-12FDA Approved: SIROLIMUS — Original Application (Ascend Laboratories, LLC)
FDA approves the original (generic) application for sirolimus from Ascend Laboratories, authorizing its marketing as an immunosuppressant. T…
-
CLINICAL_TRIALS trial_result · 2021-03-05Clinical Trial Update: Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation [Phase 2]
A Phase 2 clinical trial evaluating donor-specific immune senescence and exhaustion as biomarkers of tolerance after liver transplantation h…
-
CLINICAL_TRIALS trial_result · 2021-02-09Clinical Trial Update: Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction [Phase 1, Phase 2]
A Phase 1/Phase 2 trial evaluating donor alloantigen reactive Tregs (darTregs) for reducing calcineurin inhibitor use in liver transplant re…
-
FDA approval · 2021-01-15FDA Approved: MYFORTIC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Myfortic (mycophenolic acid) submitted by Novartis Pharmaceuticals Corporation. The approval typ…
-
FDA approval · 2021-01-15FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for mycophenolate mofetil (generic) submitted by Mylan Institutional LLC.